Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewBortezomib is a high affinity proteasome inhibitor (Ki = 0.6 nM). Inhibits growth of multiple myeloma (MM) cell lines (IC50 values in <50 nM range); induces apoptosis in MM cell lines and MM patient derived cells, including p53 mutant cell lines. Decreases adherence of MM cells lines to bone marrow stromal cells (BMSCs). Acts synergistically with dexamethasone (Cat. No. 1126). Also cytotoxic in MCF-7 breast cancer cell line (IC50 = 50 nM).
Bortezomib is also offered as part of the Tocriscreen 2.0 Max. Find out more about compound libraries available from Tocris.
M. Wt | 384.24 |
Formula | C19H25BN4O4 |
Storage | Store at -20°C |
Purity | ≥98% (HPLC) |
CAS Number | 179324-69-7 |
PubChem ID | 387447 |
InChI Key | GXJABQQUPOEUTA-RDJZCZTQSA-N |
Smiles | CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=NC=CN=C1)B(O)O |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
DMSO | 50 | 131 | |
ethanol | 10 | 27 |
The following data is based on the product molecular weight 384.24. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1.31 mM | 1.99 mL | 9.93 mL | 19.87 mL |
6.55 mM | 0.4 mL | 1.99 mL | 3.97 mL |
13.1 mM | 0.2 mL | 0.99 mL | 1.99 mL |
65.5 mM | 0.04 mL | 0.2 mL | 0.4 mL |
References are publications that support the biological activity of the product.
Teicher et al (1999) The proteasome inhibitor PS-341 in cancer therapy. Clin.Cancer Res. 5 2638 PMID: 10499643
Hideshima et al (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 61 3071 PMID: 11306489
If you know of a relevant reference for Bortezomib, please let us know.
Keywords: Bortezomib, Bortezomib supplier, PS341, proteasome, inhibitor, multiple, myeloma, high, affinity, Proteasome, 7282, Tocris Bioscience
Citations are publications that use Tocris products. Selected citations for Bortezomib include:
Vimla et al (2021) CHIP/STUB1 Ubiquitin Ligase Functions as a Negative Regulator of ErbB2 by Promoting Its Early Post-Biosynthesis Degradation. Cancers (Basel) 13 PMID: 34439093
Tomo et al (2023) ATP Consumption Is Coupled with Endocytosis in Exudated Neutrophils. Int J Mol Sci 24 PMID: 37240384
Do you know of a great paper that uses Bortezomib from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review Bortezomib and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
This brochure highlights the tools and services available from Bio-Techne to support your Targeted Protein Degradation and Induced Proximity research, including:
Degraders (e.g. PROTACs) are bifunctional small molecules, that harness the Ubiquitin Proteasome System (UPS) to selectively degrade target proteins within cells. They consist of three covalently linked components: an E3 ubiquitin ligase ligand, a linker and a ligand for the target protein of interest. Authored in-house, this poster outlines the generation of a toolbox of building blocks for the development of Degraders. The characteristics and selection of each of these components are discussed. Presented at EFMC 2018, Ljubljana, Slovenia